@article{Jiarpinitnun_Sitathanee_Dhanachai_2009, title={The Results of High-dose Rate Intracavitary Brachytherapy for Uterine Cervical Carcinoma in Ramathibodi Hospital}, volume={32}, url={https://he02.tci-thaijo.org/index.php/ramajournal/article/view/175350}, abstractNote={<p><strong>Objectives: </strong>To study results of high-dose-rate brachytherapy (HDR-BCT) for the treatment of cervical cancer patients in Ramathibodi Hospital in terms of tumor control, survival and treatment complications and to identify factors that may impact on local control.</p> <p><strong>Materials and Methods:</strong> Retrospective analysis was performed on patients with stage IA-IVA cervical cancer treated with a combination of external beam radiotherapy (EBRT) and HDR-BCT in Ramathibodi hospital during March 1999 to June 2001. The Kaplan-Meier method was used for survival analysis. Univariate and Multivariate analysis was performed using log-rank test and Cox proportional hazard regression model to identify factors associated with local control rates.</p> <p><strong>Results: </strong>There were 263 patients included in this study (5.3% stage I, 52.8% stage II, 41.8% stage II). The median follow-up time was 66 months (3-113 months). Seventy-one patients (27%) were lost to follow-up. Chemotherapy was delivered in 45 patients. Early stage patients received 40-50.4 Gy whole pelvic EBRT plus 3-4 intracavitary brachytherapy sessions with a fraction size of 3-7 Gy. Patients with advanced stage underwent EBRT to the pelvis to a dose of 40-60 Gy followed by 2-4 sessions of HDR- BCT of 4-7.5 Gy. Median low-dose-rate equivalent dose at point A was 73 Gy and 75 Gy in early and advanced stage, respectively. The 5-year overall survival, disease-free, and local control rates for all patients were 70%, 70%, and 80%, respectively. The 5-year LC rates according to stage were 92% in early stage and 77% in advanced stage. Stage and quality of brachytherapy were independent prognostic factors of local control. Severe (grade 3 and 4) late GI and GU complication rates were 3.1%, and 1.6%, respectively.</p> <p><strong>Conclusion:</strong> The combination of EBRT and HDR-BCT, as used in Ramathibodi hospital, can produce favorable outcome and acceptable rates of late complication when compared to other centers in treatment of cervical cancer.</p>}, number={3}, journal={Ramathibodi Medical Journal}, author={Jiarpinitnun, Chuleeporn and Sitathanee, Chomporn and Dhanachai, Mantana}, year={2009}, month={Sep.}, pages={111–122} }